PLANO, Texas--(BUSINESS WIRE)--Jun 27, 2025--
L&T Technology Services (BSE: 540115, NSE: LTTS), a leading global engineering and technology services company, has unveiled its state-of-the-art Engineering Design Center in Plano, Texas. This investment underscores LTTS’ commitment to delivering advanced solutions in AI & Tech and establish more near shore centers tailored to the evolving needs of our clients.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250626047990/en/
As an ITAR-compliant facility, the center is equipped to design, develop, and test defense-related products and systems. The new design hub will also focus on advanced cybersecurity solutions, including a Security Operations Center (SoC), an enabler for Smart City technologies. Starting with a capacity to house 100 engineers, the center aims to create more than 350 high-skilled jobs in core business segments including Mobility and Tech.
Inaugurated by the Honorable Mayor of Plano, John B. Muns;Vice President at Caterpillar,Tim Graham; Honorable Consul General of India in Houston, Manjunath Chenneerappa; and President & Executive Director (Mobility & Tech) at LTTS,Alind Saxena, the center exemplifies innovation and cross-pollination of technologies. During the inauguration, LTTS' engineers demonstrated capabilities such as:
This milestone strengthens Texas’ position as a hub for innovation in AI, Generative AI, and Digital Manufacturing, while underscoring LTTS’ leadership in building intelligent, innovative products.
U.S. Senator Ted Cruz commended LTTS on the launch of the new engineering design center, stating,“L&T Technology Services has been an example of engineering innovation and a provider of jobs here in Texas. This new center is a testament to your unwavering commitment to excellence, ingenuity and the future of the Lone Star State. I am thrilled to see that L&T Technology Services’ new center will create quality jobs and provide employment to as many as 400 engineers. When companies like L&T Technology Services thrive, it sends a powerful message - Texas is open for business, and we are ready to lead in the industries of tomorrow.”
Mayor of Plano, John B. Muns, remarked,“This center represents innovation at its finest and marks an important step forward for our region. With 100 professionals to start and plan to grow to over 350 engineering jobs, LTTS is not just creating opportunities, they are helping shape the future of advanced technology development and smart manufacturing. I thank LTTS for investing in North Texas and for contributing to a brighter, more innovative future.”
Congressman Pat Fallon, 4 th District of Texas, welcomed LTTS’ investment.“It’s an exciting day for Plano and Texas as we welcome L&T Technology Services’ new Engineering Design Center. This center is a testament to the State of Texas’ reputation as a leader in innovation and high-tech excellence, bringing over 350 new age engineering jobs that will fuel growth in smart manufacturing and digital transformation. LTTS’ investment in our community showcases the bright future we are building together.”
“This center is more than just an engineering hub — it’s a symbol of our promise to bring innovation closer to our clients across all major segments and industries that we serve,” said Alind Saxena, President & Executive Director - Mobility & Tech, L&T Technology Services. “Plano is now a critical pillar in our global delivery model, with proximity to our clients, while working closely with local partners and talent to co-create industry-defining solutions right here in Texas.”
About L&T Technology Services Ltd
L&T Technology Services (LTTS) is a global leader in engineering and technology services. A listed subsidiary of Larsen & Toubro (L&T), we offer design, development, testing, and sustenance services across products and processes.
Purposeful. Agile. Innovation. is how we drive growth across the Mobility, Sustainability and Tech segments. Our customer base includes 69 Fortune 500 companies and 57 top ER&D companies across industrial products, medical devices, transportation, telecom & hi-tech, and process industries. Headquartered in India, we have over 24,250 employees across 23 global design centers, 30 global sales offices, and 108 innovation labs, as of March 31, 2025.
For additional information about L&T Technology Services log on to www.LTTS.com.
The center was inaugurated by the Honorable Mayor of Plano, John B. Muns; Vice President at Caterpillar, Tim Graham; Honorable Consul General of India in Houston, Manjunath Chenneerappa; President & Executive Director (Mobility & Tech) at LTTS, Alind Saxena; and Chief Delivery Officer (Americas) & Head of Corporate Strategy at LTTS, Bhanu Gopalam.
BEIJING & ALAMEDA, Calif. & TAIPEI--(BUSINESS WIRE)--Jan 9, 2026--
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109621764/en/
The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed.
“This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection of leading bispecific antibody and dual-payload ADC candidates,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Based on the preclinical research conducted to date, we believe that the combination of Biocytogen’s RenLite ® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compelling approach for the development of next-generation dual-payload bispecific ADCs.”
“This option-based framework allows us to systematically assess how dual-payload conjugation strategies can be applied to bispecific antibody formats,” said Sonny Hsiao, Ph.D., Chairman and CEO of Acepodia. “This collaboration reflects our focus on disciplined, data-driven AD2C platform expansion.”
The expanded partnership is intended to leverage complementary platform strengths to advance next-generation ADC designs with the potential to improve upon certain limitations observed in conventional ADC programs. The joint team is progressing towards candidate evaluation milestones, with advancement decisions informed by ongoing research results and Acepodia’s internal governance and option exercise criteria.
About Biocytogen
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.
Biocytogen has independently developed its proprietary RenMice ® (RenMab™/ RenLite ® / RenNano ® /RenTCR™/ RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice ® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
About Acepodia
Acepodia is transforming cancer and autoimmune disease treatment with first-in-class immune cell engagers that deliver enhanced and targeted potency through multiple conjugation platforms. Leveraging a family of bio-orthogonal click chemistry approaches originating from Nobel Prize laureate Carolyn Bertozzi’s lab, Acepodia’s platforms are designed to improve safety and offer broad applicability across hematologic and solid tumor cancers, as well as autoimmune diseases. Acepodia’s conjugation platforms are designed for modular integration across antibodies, immune cells, and payload architectures, enabling flexible application across diverse therapeutic modalities. By combining innovative science with a patient-centric vision, Acepodia aims to bring powerful, next-generation therapies to patients underserved by today’s treatments. For more information, please visit https://www.acepodia.com/.
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)
